Rankings
▼
Calendar
TEVA Q1 2025 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$37B
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.9B
+1.9% YoY
Gross Profit
$1.9B
48.2% margin
Operating Income
$519M
13.3% margin
Net Income
$214M
5.5% margin
EPS (Diluted)
$0.18
QoQ Revenue Growth
-8.0%
Cash Flow
Operating Cash Flow
-$105M
Free Cash Flow
-$232M
Stock-Based Comp.
$34M
Balance Sheet
Total Assets
$38.4B
Total Liabilities
$32.1B
Stockholders' Equity
$6.3B
Cash & Equivalents
$1.7B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.9B
$3.8B
+1.9%
Gross Profit
$1.9B
$1.8B
+6.0%
Operating Income
$519M
-$218M
+338.1%
Net Income
$214M
-$139M
+254.0%
Revenue Segments
Product
$3.4B
87%
Distribution Service
$384M
10%
Product and Service, Other
$76M
2%
License
$36M
1%
Geographic Segments
North America Segment
$1.9B
52%
Europe Segment
$1.2B
32%
International Markets
$582M
16%
← FY 2025
All Quarters
Q2 2025 →